Swiss CRO Atheris Laboratories has signed a deal with Debiopharm to help develop a peptide cancer drug, optimizing leads for an innovative venom-derived treatment.
India's TCG Lifesciences has signed up to handle early phase work for Debiopharm's drug-resistant bacteria program, helping the Swiss drug developer as it chases a share of the antibiotics market.
The preclinical CRO Cenix BioScience has struck a deal to work with Germany's Debiopharm, putting its experts to work finding predictive biomarkers that can be used to advance the biotech's cancer drug candidates.
German CRO Cenix BioScience has agreed to handle preclinical work for Debiopharm's oncology pipeline, using its high-content assays to identify biomarkers.
Swiss drugmaker Debiopharma has teamed up with India's Shasun Pharmaceuticals, striking a deal with the CMO to manufacture Huperzine-A, a drug designed to improve cognitive performance in patients with Alzheimer's disease.
Debiopharm has signed on as the latest drug developer to attend Yale laboratories for some help with early-stage research work. Yale's "leadership in marrying chemistry and biology to identify and
Switzerland's Debiopharm will pay up to $25 million in R&D milestones to partner with Marina Biotech on the company's preclinical program for non-muscle invasive bladder cancer. Marina can look
Curis will receive $8 million in milestone payments from its Swiss partner Debiopharm after French authorities approved a CTA for a study of Debio 0932, a potential treatment for tumors. Debiopharm
Novartis has signed a deal with Switzerland's Debiopharm to develop and market Debio 025 (alisporivir), an antiviral agent for hepatitis C. Debio 025, which is currently in Phase II, is the first in
Debiopharm believes it can succeed with a cancer drug that ran straight into a late-stage brick wall at Pfizer. In a deal announced today, the developer will conduct a Phase III trial of tremelimumab